www.tekavo.in

The Focal point of research at invictus is to adopt multidisciplinary approach in discovering innovative therapies to braoden the pipeline with the goal of a paradigm shift in cancer care.Antibody Drug Conjugates (ADCs) represent a promising therapeutic strategy for tumor-specific drug delivery, sparing healthy tissues. Invictus is developing a portfolio of ADC's based on its proprietary linker chemistryHere, I am a Part of Research team whose working on Supra molecular Antibody drug Conjugates (ADC) as well as Small molecule API synthesis. Antibody Drug Conjugates or ADCs are a new class of highly potent biopharmaceutical drugs designed as a Targeted therapy for the treatment of people with cancer.ADCs are complex molecules composed of an antibody (a whole mAb or an antibody fragment such as a single-chain variable fragment linked, via a stable, chemical, linker with labile bonds, to a biological active cytotoxic (anticancer) payload or drug.

National Institute of Pharmaceutical Education and Research (NIPER) is the first national level institute in pharmaceutical sciences with a proclaimed objective of becoming a centre of excellence for advanced studies and research in pharmaceutical sciences. The Government of India has declared NIPER as an 'Institute of National Importance'. It is an autonomous body set up under the aegis of Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India. The Institute is conceived to provide leadership in pharmaceutical sciences and related areas not only within the country, but also to the countries in South East Asia, South Asia and Africa. NIPER is a member of Association of Indian Universities and Association of Commonwealth Universities.